AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.
first published: May 25, 2011 01:26 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Sideways But Holds 26,000 Ahead Of MPC Rate Decision| IT & Realty Upbeat| Closing Bell Live
Live: RBI Policy Expectations| Rupee Slide, Strong GDP & Soft Inflation – Will MPC Cut Or Pause?
Nifty Holds Key Support; Volatile Trade Likely on Sensex Expiry | Opening Bell Live
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
